Amylyx Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) is a U.S.-based clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, United States. The company was founded in 2013 by Joshua Cohen and Justin Klee and was later incorporated in Delaware in 2014. Its corporate identity was built around a long-standing mission to develop therapies for severe diseases with high unmet medical need, particularly neurodegenerative disorders and selected rare diseases. From an investor perspective, Amylyx remains a development-driven company whose valuation is closely tied to clinical execution, regulatory progress, and the success of a small number of lead programs. ([amylyx.com](https://www.amylyx.com/our-company/?utm_source=openai)) Historically, Amylyx first gained prominence through AMX0035, its lead program in amyotrophic lateral sclerosis (ALS). Over time, however, the company has broadened its focus and now presents itself as a pipeline company rather than a single-asset story. Its current portfolio includes AMX0114, an antisense oligonucleotide candidate targeting calpain-2 in ALS, avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH), and AMX0318, a newer GLP-1 receptor antagonist development candidate identified in collaboration with Gubra. This shift indicates a more diversified R&D strategy, but one still anchored in highly specialized, mechanistically differentiated programs. ([investors.amylyx.com](https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-new-safety-and-tolerability?utm_source=openai)) Competitive positioning in biopharma is centered on rare and serious diseases, where clinical data quality, regulatory designations, and speed to proof-of-concept matter more than broad commercial scale. Amylyx has built credibility in ALS and related neurology areas, while also pursuing adjacent opportunities where it can potentially create value with focused, niche therapies. The company’s operating footprint is primarily in the United States, with headquarters in Cambridge, Massachusetts, and it has also described historical operations in Canada, EMEA, and Japan. For market context, AMLX is listed on the Nasdaq, which is the relevant U.S. exchange for international investors screening U.S.-listed healthcare names. ([amylyx.com](https://www.amylyx.com/news/amylyx-a-company-dedicated-to-discovery-and-development-of-treatments-for-als-and-other-neurodegenerative-diseases-establishes-a-japanese-subsidiary?utm_source=openai)) Recent developments are especially important for the investment case. In 2026, Amylyx completed enrollment in the pivotal Phase 3 LUCIDITY trial of avexitide in PBH, with topline data expected in Q3 2026. The company also launched a U.S. Expanded Access Program for avexitide in early May 2026, allowing certain adults with PBH to access the investigational therapy under defined conditions. In its first-quarter 2026 disclosures, Amylyx stated that its cash position should fund operations into 2028, which helps reduce near-term financing pressure, though the company remains pre-commercial in its new pipeline focus. For investors, the key takeaway is that AMLX is a U.S. Nasdaq-listed biotech with a clinically meaningful near-term catalyst, but still a high-risk, high-optional-value profile dependent on trial outcomes. ([amylyx.com](https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-completion-of-enrollment-in-pivotal-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia?utm_source=openai))